Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Feb. 29, 2016	Apr. 04, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Feb. 29, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	ANGO
Entity Registrant Name	ANGIODYNAMICS INC
Entity Central Index Key	0001275187
Current Fiscal Year End Date	--05-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		36,367,049

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Income Statement [Abstract]
Net sales	$ 87,384	$ 86,597	$ 260,321	$ 266,077
Cost of sales	43,900	48,746	127,829	134,745
Gross profit	43,484	37,851	132,492	131,332
Operating expenses
Research and development	5,808	6,855	18,189	19,642
Sales and marketing	20,301	19,355	61,429	60,405
General and administrative	6,784	6,917	22,300	22,213
Amortization of intangibles	4,458	5,106	13,356	13,182
Change in fair value of contingent consideration	(31)	(10,044)	630	(8,626)
Acquisition, restructuring and other items, net	3,042	18,779	9,098	23,745
Medical device excise tax	435	1,034	2,416	3,105
Total operating expenses	40,797	48,002	127,418	133,666
Operating income	2,687	(10,151)	5,074	(2,334)
Other (expenses) income
Interest expense	(809)	(859)	(2,607)	(2,451)
Interest income	2	2	4	3
Other expense	(868)	(971)	(2,861)	(2,950)
Total other expenses, net	(1,675)	(1,828)	(5,464)	(5,398)
Income (loss) before income tax expense (benefit)	1,012	(11,979)	(390)	(7,732)
Income tax expense (benefit)	382	(7,717)	99	(5,278)
Net income (loss)	$ 630	$ (4,262)	$ (489)	$ (2,454)
Income (loss) per share
Basic (in usd per share)	$ 0.02	$ (0.12)	$ (0.01)	$ (0.07)
Diluted (in usd per share)	$ 0.02	$ (0.12)	$ (0.01)	$ (0.07)
Basic weighted average shares outstanding (in shares)	36,146	35,755	36,083	35,568
Diluted weighted average shares outstanding (in shares)	36,390	35,755	36,083	35,568

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Statement of Comprehensive Income [Abstract]
Net Income (loss)	$ 630	$ (4,262)	$ (489)	$ (2,454)
Other comprehensive income (loss), before tax:
Unrealized gain (loss) on interest rate swap	58	133	219	289
Unrealized gain (loss) on marketable securities	27	(17)	2	(129)
Foreign currency translation gain (loss)	79	(624)	(360)	(728)
Other comprehensive income (loss), before tax	164	(508)	(139)	(568)
Income tax (expense) benefit related to items of other comprehensive income	(30)	(43)	(83)	(59)
Other comprehensive income (loss), net of tax	134	(551)	(222)	(627)
Total comprehensive income (loss), net of tax	$ 764	$ (4,813)	$ (711)	$ (3,081)

Consolidated Balance Sheets - USD ($) $ in Thousands	Feb. 29, 2016	May. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 21,897	$ 18,391
Marketable securities	1,666	1,689
Accounts receivable, net of allowances of $3,673 and $3,043 respectively	54,446	58,428
Inventories	65,792	67,388
Prepaid income taxes	917	770
Prepaid expenses and other	4,683	4,783
Total current assets	149,401	151,449
Property, plant and equipment, net	49,693	54,560
Other assets	5,524	5,288
Intangible assets, net	168,080	181,806
Goodwill	361,252	361,252
Deferred income taxes, long-term	19,563	19,268
TOTAL ASSETS	753,513	773,623
CURRENT LIABILITIES
Accounts payable	18,067	23,668
Accrued liabilities	17,979	18,331
Income taxes payable	380	439
Current portion of long-term debt	12,500	8,750
Current portion of contingent consideration	12,653	9,969
Total current liabilities	61,579	61,157
Long-term debt, net of current portion	113,910	128,910
Deferred income taxes, long-term	1,119	1,119
Contingent consideration, net of current portion	25,243	37,415
Other long-term liabilities	917	0
Total liabilities	$ 202,768	$ 228,601
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	$ 0	$ 0
Common stock, par value $.01 per share, 75,000,000 shares authorized; 36,367,049 and 36,043,725 shares issued and 36,224,744 and 35,901,420 shares outstanding at February 29, 2016 and May 31, 2015, respectively	363	360
Additional paid-in capital	526,532	520,101
Retained earnings	27,744	28,233
Treasury stock, 142,305 shares, at cost	(2,104)	(2,104)
Accumulated other comprehensive loss	(1,790)	(1,568)
Total stockholders’ equity	550,745	545,022
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 753,513	$ 773,623

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Feb. 29, 2016	May. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 3,673	$ 3,043
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	36,367,049	36,043,725
Common stock, shares outstanding	36,224,744	35,901,420
Treasury stock, shares	142,305	142,305

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
Statement of Cash Flows [Abstract]
Noncash Merger Related Costs	$ 0	$ 349
Cash flows from operating activities:
Net income (loss)	(489)	(2,454)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	21,399	22,776
Stock based compensation	4,500	4,389
Change in fair value of contingent consideration	630	(8,626)
Deferred income taxes	(373)	(4,138)
Fixed and intangible asset impairments and disposals	675	9,188
Impairment loss on indefinite-lived intangible assets	0	6,400
Change in accounts receivable allowances	1,355	659
Other	0	(70)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	2,492	3,535
Inventories	1,457	(7,476)
Prepaid expenses and other assets	(241)	(2,319)
Accounts payable, accrued and other liabilities	(4,733)	(6,428)
Net cash provided by operating activities	26,672	15,436
Cash flows from investing activities:
Additions to property, plant and equipment	(1,895)	(11,038)
Acquisition of intangibles	(18)	(1,004)
Proceeds from sale or maturity of marketable securities	25	0
Net cash used in investing activities	(3,888)	(12,042)
Cash flows from financing activities:
Proceeds from issuance of and borrowings on long-term debt	0	15,000
Repayment of long-term debt	(11,250)	(8,750)
Payment of contingent consideration previously established in purchase accounting	(9,850)	(11,222)
Proceeds from exercise of stock options and employee stock purchase plan	1,933	5,613
Net cash provided by (used in) financing activities	(19,167)	641
Effect of exchange rate changes on cash and cash equivalents	(111)	(436)
Increase (decrease) in cash and cash equivalents	3,506	3,599
Cash and cash equivalents at beginning of period	18,391	16,105
Cash and cash equivalents at end of period	21,897	19,704
Supplemental disclosure of non-cash investing and financing activities:
Contractual obligations for acquisition of fixed assets	37	211
Payments for Repurchase of Warrants	$ (2,000)	$ 0

Consolidated Statement of Stockholders' Equity - 9 months ended Feb. 29, 2016 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]
Beginning Balance at May. 31, 2015	$ 545,022,000	$ 360,000	$ 520,101,000	$ 28,233,000	$ (1,568,000)	$ (2,104,000)
Beginning Balance, Shares at May. 31, 2015		36,043,725
Beginning Balance,Treasury Shares at May. 31, 2015	(142,305)
Net income (loss)	$ (489,000)			(489,000)
Exercise of stock options	793,000	$ 1,000	792,000
Exercise of stock options, Shares		52,578
Purchase of common stock under ESPP	1,471,000	$ 1,000	1,470,000
Purchase of common stock under ESPP, Shares		137,957
Issuance of performance shares	(330,000)	$ 1,000	(331,000)
Issuance of performance shares, Shares		132,789
Stock based compensation	4,500,000		4,500,000
Other comprehensive income, net of tax	(222,000)				(222,000)
Ending Balance at Feb. 29, 2016	$ 550,745,000	$ 363,000	$ 526,532,000	$ 27,744,000	$ (1,790,000)	$ (2,104,000)
Ending Balance, Shares at Feb. 29, 2016		36,367,049
Ending Balance,Treasury Shares at Feb. 29, 2016	(142,305)					(142,305.000)

Consolidated Condensed Financial Statements	9 Months Ended
Consolidated Condensed Financial Statements	Feb. 29, 2016
Accounting Policies [Abstract]
Consolidated Condensed Financial Statements	CONSOLIDATED CONDENSED FINANCIAL STATEMENTS The consolidated condensed balance sheet as of February 29, 2016, the consolidated condensed statement of stockholders’ equity and the consolidated condensed statement of cash flows for the nine months ended February 29, 2016 and the consolidated condensed statements of income (loss) and the consolidated condensed statements of comprehensive income (loss) for the three and nine months ended February 29, 2016 and February 28, 2015 have been prepared by us without audit. The consolidated condensed balance sheet as of May 31, 2015 was derived from audited consolidated condensed financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended February 29, 2016 (and for all periods presented) have been made. The unaudited interim consolidated condensed financial statements for the three and nine months ended February 29, 2016 and February 28, 2015 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated. Recent Developments On March 31, 2016, Joseph DeVivo, President and Chief Executive Officer, decided to pursue other interests and on April 4, 2016, James C. Clemmer was appointed as the new President and Chief Executive Officer. During the second quarter of fiscal 2016, Mark Frost resigned as Executive Vice President and Chief Financial Officer (CFO). Michael Trimarchi, Vice President and Global Controller, has assumed the responsibilities as principal accounting officer of the Company and as interim CFO. The Company is in the process of identifying a permanent successor. On December 18, 2015, President Obama signed into law H.R. 2029, the “Consolidated Appropriations Act, 2016”, which included a two-year moratorium on the medical device excise tax, effective January 1, 2016. The 2.3 percent tax on sales of medical devices (except certain devices sold at retail) was enacted as part of the Affordable Care Act in 2010 and applied to device sales beginning on January 1, 2013. Absent further legislative action, the tax will be automatically be reinstated for medical device sales starting on January 1, 2018. We have incurred $12.0 million cumulatively since the enactment of the tax on January 1, 2013 through February 29, 2016, our third quarter of fiscal 2016. In the absence of this tax, the Company will seek opportunities to further invest in growth drivers to create long-term shareholder value. On November 17, 2015, the Company received a letter from the FDA closing out the warning letter the Company received from FDA in January 2011 regarding certain promotional activities related to the NanoKnife System. On November 25, 2015, the Company received letters from the FDA closing out the warning letters the Company received from FDA in May 2011 related to the Company’s Queensbury facility and in November 2014 related to the Company’s Glens Falls facility. These close out letters resolved all outstanding warning letters against the Company.

Inventories

9 Months Ended

Feb. 29, 2016

Inventory Disclosure [Abstract]

Inventories

INVENTORIES

Inventories are stated at lower of cost (using the first-in, first-out method) or market. As of February 29, 2016 and May 31, 2015, inventories consisted of the following:



	Feb 29, 2016		May 31, 2015
	(in thousands)
Raw materials	$	28,716	$	28,040
Work in process	11,605		11,910
Finished goods	25,471		27,438
Inventories	$	65,792	$	67,388

Other Assets	9 Months Ended
Other Assets	Feb. 29, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets	OTHER ASSETS On March 2, 2015, the Company filed an 8-K stating that it executed a non-binding letter of intent to enter into a strategic relationship with privately-held EmboMedics Inc., which develops injectable and resorbable embolic microspheres. On April 9, 2015 the Company entered into a License, Distribution, Manufacturing and Purchase Option Agreement with EmboMedics Inc, subject to certain approvals by EmboMedics shareholders. Under the terms of the agreement, AngioDynamics receives an exclusive worldwide license to market and sell, upon regulatory clearances, EmboMedics’ microsphere technology. AngioDynamics will also control manufacturing of the products. On December 7, 2015, AngioDynamics made an initial $2.0 million purchase of non-transferable warrants in a subsidiary of EmboMedics which become exercisable upon a change of control of EmboMedics. This initial investment is recorded at cost and the Company will review for impairment at each balance sheet date. The warrants are not exercisable at the original issue date or the balance sheet date as they only become exercisable upon a change of control, termination of the agreement or delivery of an offer notice. Based on the achievement of certain development activities, the Company will make an additional $5.0 million purchase of non-transferable warrants and an additional $4.0 million in milestone payments based on regulatory approvals. In the future, AngioDynamics could execute an exclusive option to acquire this subsidiary of EmboMedics.

Goodwill and Intangible Assets

9 Months Ended

Feb. 29, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Intangible assets other than goodwill and indefinite lived intangible assets are amortized over their estimated useful lives, which range between two and eighteen years, on either a straight-line basis or proportionately to the benefit being realized. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment, based on estimated future cash flows, whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.

We consider our business to be a single operating segment entity, and a single reporting unit engaged in the development, manufacture and sale on a global basis of medical devices for vascular access, peripheral vascular disease, oncology and surgery.

Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated costs based on respective fair market values at the date of acquisition.

For goodwill, the impairment test requires a comparison of the estimated fair value of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge.

To determine fair value of our single reporting unit we utilized a market-based approach and an income approach. We determined the discounted cash flow as the best indicator to determine fair value and therefore assigned a weight of 75% with the remaining 25% assigned to the market approach.

Under the market-based approach, we utilized information of our Company as well as publicly available information of certain peer companies within our industry to determine earnings multiples (EBITDA).

Under the income approach, we determined fair value based on estimated future cash flows of the reporting unit, discounted by our estimated weighted-average cost of capital, which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. We used a discount rate of 12.5% to calculate the fair value of our reporting unit.

Use of the income approach in determining the fair value of a reporting unit requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. These assumptions are highly sensitive and changes in these estimates could result in impairment. We applied gross margin assumptions, showing improvement over historical trends, improvements over historical trends of revenue of certain product lines and used a capitalization rate of 8.5% to calculate the terminal value of our reporting unit.

We completed our annual goodwill impairment test as of December 31, 2015. At December 31, 2015, our reporting unit is the same as our one reportable segment. Our assessment of goodwill impairment indicated that the fair value of our reporting unit exceeded its carrying value and therefore goodwill was not impaired. The fair value of our reporting unit exceeded its carrying value by 9.2%.

At times our stock market capitalization has been lower than our shareholders’ equity or book value. However, our reporting unit has continued to generate significant cash flows from operations, and we expect to continue to do so in fiscal 2016 and beyond. Furthermore, we believe that a reasonable potential buyer would offer a control premium for our business that would adequately cover the difference between our stock market capitalization and our book value. The implied control premium in our annual goodwill impairment test as of December 31, 2015 is comparable to premiums identified in recent acquisitions of companies of similar size and in similar industries.

Even though we determined that there was no goodwill impairment as of December 31, 2015, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2016.

It is not possible at this time to determine if any such future impairment charge would result or, if it does, whether such charge would be material. Events that could, in the future, result in impairment include, but are not limited to, declining sales for a significant product or in a significant geographic region.

There were no adjustments to goodwill for the nine months ended February 29, 2016.

As of February 29, 2016 and May 31, 2015, intangible assets consisted of the following:



	February 29, 2016
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
	(in thousands)							(years)
Product technologies	$	148,383	$	(48,815	)	$	99,568	10.2
Customer relationships	86,361		(45,981		)	40,380		12.0
Trademarks	28,470		(5,355		)	23,115		10.7
In process R&D acquired	3,600		—			3,600		Indefinite
Licenses	7,931		(6,514		)	1,417		7.6
Distributor relationships	900		(900		)	—		3.0
	$	275,645	$	(107,565	)	$	168,080



	May 31, 2015
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
	(in thousands)							(years)
Product technologies	$	148,776	$	(41,447	)	$	107,329	10.2
Customer relationships	86,371		(42,813		)	43,558		12.0
Trademarks	28,545		(3,229		)	25,316		10.7
In process R&D acquired	3,600		—			3,600		Indefinite
Licenses	7,913		(5,910		)	2,003		8.3
Distributor relationships	900		(900		)	—		3.0
	$	276,105	$	(94,299	)	$	181,806

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Liabilities

9 Months Ended

Feb. 29, 2016

Payables and Accruals [Abstract]

Accrued Liabilities

ACCRUED LIABILITIES

As of February 29, 2016 and May 31, 2015, accrued liabilities consisted of the following:



	Feb 29, 2016		May 31, 2015
	(in thousands)
Payroll and related expenses	$	9,129	$	9,911
Royalties	2,211		2,237
Accrued severance	—		175
Sales and franchise taxes	384		547
Interest rate swap liability	38		257
Outside services	1,420		1,087
Consignment liability	794		558
Deferred rent	29		808
Other	3,974		2,751
	$	17,979	$	18,331

Long Term Debt	9 Months Ended
Long Term Debt	Feb. 29, 2016
Debt Disclosure [Abstract]
Long Term Debt	LONG TERM DEBT On September 19, 2013, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers. The Credit Agreement provides for a $100 million senior secured term loan facility (“Term Loan”) and a $100 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans (the “Revolving Facility”, and together with the Term Loan, the “Facilities”). The proceeds of the Revolving Facility may be used for general corporate purposes of AngioDynamics and its subsidiaries. The Facilities have a five year maturity. The Term Loan has a quarterly repayment schedule equal to 5%, 5%, 10%, 15% and 65% of its principal amount in years one through five. Interest on both the Term Loan and Revolving Facility are based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.5% to 2.25% respectively. After default, the interest rate may be increased by 2.0%. The Revolving Facility will also carry a commitment fee of 0.2% to 0.35% per annum on the unused portion. Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of AngioDynamics and the Guarantors under the Facilities are secured by first priority security interests in substantially all of the assets of AngioDynamics and the Guarantors. We have entered into an interest rate swap agreement, (the “Swap Agreement”), with an initial notional amount of $100 million, to limit the effect of rising of interest rates. The Swap Agreement, which qualified for hedge accounting under authoritative guidance, was a contract to exchange floating interest rate payments for fixed interest rate payments on the outstanding balance of the loan over the life of the agreement without the exchange of the underlying notional amounts. The Swap Agreement provides for a fixed rate of 0.74% above the applicable rate provided for in the Credit Agreement. The Swap Agreement matures in May 2016 at which point our interest rate will float. On September 19, 2013, we borrowed $100 million under the Term Facility and approximately $41.4 million under the Revolving Facility to repay the Former Credit Agreement. As of February 29, 2016, $85.0 million and $41.4 million were outstanding under the Term Facility and Revolving Facility, respectively. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. The first financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated adjusted EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.35 to 1.00. The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated adjusted EBITDA of not greater than 3.75 to 1.00. We were in compliance with both covenants as of February 29, 2016.

Income Taxes

9 Months Ended

Feb. 29, 2016

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The following table presents the components of income tax expense (benefit) for the three and nine months ended February 29, 2016 and February 28, 2015 (in thousands of dollars):



	Three Months Ended						Nine Months Ended
	Feb 29, 2016			Feb 28, 2015			Feb 29, 2016			Feb 28, 2015
Income (loss) before Income Taxes	$	1,012		$	(11,979	)	$	(390	)	$	(7,732	)
Less discrete book income (expense):
Non-taxable portion of change in fair value of contingent consideration	—			9,229			170			9,229
Taxable portion of revaluation of contingent consideration	480			1,323			480			1,323
Morpheus product recall and discontinuance	—			(6,145		)	—			(6,145		)
Impairment of Automated Power Injector fixed asset	—			(8,200		)	—			(8,200		)
Impairment of indefinite-lived intangible asset	—			(6,400		)	—			(6,400		)
Ordinary income (loss) before income taxes	532			(1,786		)	(1,040		)	2,461

Income tax expense (benefit) based on ordinary income (loss) at estimated tax rates	$	310		$	(461	)	$	(483	)	$	1,276
Discrete tax expense (benefit):
Morpheus product recall and discontinuance	—			(2,243		)	—			(2,243		)
Impairment of Automated Power Injector fixed asset	—			(2,993		)	—			(2,993		)
Taxable gain on revaluation of contingent consideration liability	173			483			173			483
Impairment of indefinite-lived intangible asset	—			(2,336		)	—			(2,336		)
Adjustment for elimination of the ASC 718 APIC pool	115			289			629			974
Retroactive renewal of the Research and Experimentation credit	(302		)	(519		)	(302		)	(519		)
Provision for/resolution of tax audits and contingencies, net	148			—			148			—
Adjustments to prior period tax liabilities	(62		)	63			(66		)	80
Total income tax expense (benefit)	$	382		$	(7,717	)	$	99		$	(5,278	)

The estimated full year effective tax rate prior to discrete items was 46.4% in the third quarter of fiscal 2016, as compared to 51.8% for the same period in fiscal 2015. The tax rates are greater than the 35% US statutory tax rate in both periods primarily due to the impact of non-deductible expenses (such as the non-deductible portion of meals and entertainment, non-deductible interest on contingent payments and non-deductible stock based compensation related to employee stock purchase plan). The level of ordinary income and permanent items were consistent of each of the fiscal periods.

Our ASC 718 APIC pool was depleted during fiscal year 2014. Prior to its depletion, the APIC pool was reduced when share-based compensation cost previously recognized by us was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting. Due to its depletion we recorded a discrete tax expense in the three and nine months ended February 29, 2016 and February 28, 2015, as noted in the above table.

During the third quarter of fiscal 2016, the Consolidated Appropriations Act of 2016 (H.R. 2029) was enacted and permanently extended the research credit effective January 1, 2015. Accordingly, the retroactive benefit related to this renewal has been reflected in our third quarter results.

We have recorded a net deferred tax asset in the US of $19.8 million which includes the benefit of $149.2 million of loss carryforwards, which expire as follows:



Expiration Date	NOL Available (in thousands)
FY 2017	$	802
FY 2019	11,898
FY 2020	8,128
FY 2022	7,526
FY 2023	2,346
FY 2027	20,167
FY 2028	22,527
FY 2029	27,684
FY 2030	28,043
FY 2031	5,647
FY 2032	600
FY 2033	1,345
FY 2034	—
FY 2035	12,513

The Company’s analysis of the need for a valuation allowance considered that the Company has incurred a cumulative loss before taxes in the U.S. over the three year period ended February 29, 2016. A majority of the cumulative loss has been caused by the charges associated with the product recall and discontinuance and the impairment of fixed and intangible assets recorded in the quarter ended February 28, 2015, as well as restructuring and integration expenses in the period since the acquisition of Navilyst Medical in May 2012. We anticipate a return to profitability in fiscal 2016. Consideration has also been given to our history of not having Federal tax loss carryforwards expire unused, as well as the period over which the net deferred tax assets can be realized, including the expiration of our loss carryforwards and IRC Section 382 limitations.

Based on our assessment, it is more likely than not that our U.S. net deferred tax asset will be realized through future taxable earnings, the reversal of existing taxable temporary differences, and tax planning strategies. Accordingly no valuation allowance has been recorded on this net asset. We will continue to assess the need for a valuation allowance in the future.

If future results are less than projected in the U.S. and if tax planning alternatives do not offset those effects, a valuation allowance may be required to reduce the deferred tax asset, which could have a material impact on our results of operations in the period in which it is recorded. While the net deferred tax asset at February 29, 2016 is $19.8 million, if the Company were required to record a valuation allowance it could be $15.3 million greater than this amount due to deferred tax liabilities related to intangibles that have an indefinite reversal period.

Share-Based Compensation	9 Months Ended
Share-Based Compensation	Feb. 29, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION We have two stock-based compensation plans that provide for the issuance of up to approximately 6.8 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to our employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to our employees, directors and other service providers. We also have an employee stock purchase plan. For the three months ended February 29, 2016 and February 28, 2015, share-based payment expense was $1.6 million and $1.5 million, respectively. For the nine months ended February 29, 2016 and February 28, 2015, share-based payment expense was $4.5 million and $4.4 million, respectively. In the three and nine months ended February 29, 2016 and February 28, 2015, the company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of our shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award. In the first quarter of fiscal year 2016 and 2015, the company granted performance share awards under the 2004 Plan to certain employees. The awards may be earned by achieving relative performance levels over the three year requisite service period. The performance criteria are based on the total shareholder return ("TSR") of the company's common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards are based on the closing trading value of our shares on the date of grant and use a Monte Carlo simulation model. As of February 29, 2016, there were $11.6 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The company has sufficient shares to satisfy expected share-based payment arrangements.

Earnings Per Share

9 Months Ended

Feb. 29, 2016

Earnings Per Share [Abstract]

Earnings Per Share

EARNINGS PER SHARE

Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. In addition, diluted earnings per share include the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not antidilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.

The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 29, 2016 and February 28, 2015 (in thousands):



	Three Months Ended		Nine Months Ended
	Feb 29, 2016	Feb 28, 2015	Feb 29, 2016	Feb 28, 2015
Basic	36,146	35,755	36,083	35,568
Effect of dilutive securities	244	—	—	—
Diluted	36,390	35,755	36,083	35,568

Securities excluded as their inclusion would be anti-dilutive	3,394	362	3,038	674

Segment and Geographic Information

9 Months Ended

Feb. 29, 2016

Segment Reporting [Abstract]

Segment and Geographic Information

SEGMENT AND GEOGRAPHIC INFORMATION

We consider our business to be a single operating segment entity engaged in the development, manufacture and sale on a global basis of medical devices for vascular access, peripheral vascular disease, oncology and surgery. Our chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.

The table below summarizes net sales by product category (in thousands of dollars):



	Three Months Ended				Nine Months Ended
	Feb 29, 2016		Feb 28, 2015		Feb 29, 2016		Feb 28, 2015
Net sales
Peripheral Vascular	$	49,785	$	46,195	$	147,943	$	142,996
Vascular Access	24,911		26,400		74,576		80,793
Oncology/Surgery	11,998		13,066		35,706		39,062
Supply Agreement	690		936		2,096		3,226
Total	$	87,384	$	86,597	$	260,321	$	266,077

The table below presents net sales by geographic area based on external customer location (in thousands of dollars):



	Three Months Ended				Nine Months Ended
	Feb 29, 2016		Feb 28, 2015		Feb 29, 2016		Feb 28, 2015
Net sales
United States	$	69,513	$	68,410	$	208,529	$	208,848
International	17,181		17,251		49,696		54,003
Supply Agreement	690		936		2,096		3,226
Total	$	87,384	$	86,597	$	260,321	$	266,077

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Fair Value

9 Months Ended

Feb. 29, 2016

Fair Value Disclosures [Abstract]

Fair Value

FAIR VALUE

Our financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable, an interest rate swap agreement and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. The marketable securities and interest rate swap agreement have been recorded at their fair value based on a valuation received from an independent third party. The contingent consideration has been recorded at fair value using the income approach.

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This policy establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value which are provided in the table below.



Level 1	Quoted prices in active markets for identical assets or liabilities. Level 1 assets include money market funds that are traded in an active exchange market.



Level 2	Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. When quoted market prices are unobservable, we obtain pricing information from an independent pricing vendor. The pricing vendor uses various pricing models for each asset class that are consistent with what other market participants would use. The inputs and assumptions to the model of the pricing vendor are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers, and other market-related data. The pricing vendor considers all available market observable inputs in determining the evaluation for a security. Thus, certain securities may not be priced using quoted prices, but rather determined from market observable information. Included in Level 2 assets is our interest rate swap agreement which is valued using a mid-market valuation model.



Level 3	Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category includes the auction rate securities where independent pricing information was not able to be obtained and the contingent consideration related to the acquisition of Vortex, Microsulis and Clinical Devices. Our investments in auction-rate securities were classified as Level 3 as quoted prices were unavailable since these auction rate securities issued by New York state and local government authorities failed auction. Due to limited market information, we utilized a discounted cash flow (“DCF”) model to derive an estimate of fair value for contingent considerations for all periods presented. The assumptions used in preparing the DCF model included estimates with respect to the discount rate, amount and timing of future interest and principal payments and forward projections. Assumptions associated with the auction rate securities include the interest rate benchmarks, the probability of full repayment of the principal considering the credit quality and guarantees in place, and the rate of return required by investors to own such securities given the current liquidity risk.

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 29, 2016 and May 31, 2015 (in thousands of dollars):



	Fair Value Measurements using inputs considered as:						Fair Value at February 29, 2016
	Level 1		Level 2		Level 3		Fair Value at February 29, 2016
Financial Assets
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,666	$	1,666
Total	—		—		1,666		1,666
Total Financial Assets	$	—	$	—	$	1,666	$	1,666
Financial Liabilities
Interest rate swap agreements	$	—	$	38	$	—	$	38
Contingent liability for acquisition earn out	—		—		37,896		37,896
Total Financial Liabilities	$	—	$	38	$	37,896	$	37,934


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2015
	Level 1		Level 2		Level 3		Fair Value at May 31, 2015
Financial Assets
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,689	$	1,689
Total	—		—		1,689		1,689
Total Financial Assets	$	—	$	—	$	1,689	$	1,689
Financial Liabilities
Interest rate swap agreements	$	—	$	257	$	—	$	257
Contingent liability for acquisition earn out	—		—		47,384		47,384
Total Financial Liabilities	$	—	$	257	$	47,384	$	47,641

There were no transfers in and out of Level 1, 2 and 3 measurements for the three and nine months ended February 29, 2016 and 2015.

The table below presents the changes in fair value components of Level 3 instruments in the nine months ended February 29, 2016 (in thousands of dollars):



	Financial Assets			Financial Liabilities
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)			Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

Balance, May 31, 2015	$	1,689		$	47,384
Total gains or losses (realized/unrealized):
Change in present value of contingent consideration (1)	—			630
Currency (gain) loss from remeasurement	—			(18		)
Included in other comprehensive income (loss)	2			—
Proceeds from sale or maturity of marketable securities	(25		)	—
Contingent consideration payments	—			(10,100		)
Balance, February 29, 2016	$	1,666		$	37,896

(1) Change in present value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of company performance and the amortization of the present value discount.

Contingent Liabilities for Acquisition Earn Outs

Certain of our business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the consolidated statements of income. We measure the initial liability and remeasure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements.

The fair value of our liability for contingent consideration is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on our internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. At February 29, 2016, the revenue based payments are being calculated based on our current sales forecast which is at the minimums for contingent payments.

The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 29, 2016 (in thousands of dollars):



	Fair value at		Valuation
	Feb 29, 2016		Technique	Unobservable Input	Range
Revenue based payments	$	35,114	Discounted cash flow	Discount rate	4%
				Probability of achieving sales	75-100%
				Projected fiscal year of payment	2017 - 2023
Milestone based payments	2,782		Discounted cash flow	Discount rate	16%
				Probability of achieving milestone	75-100%
				Projected fiscal year of payment	2017
Total	$	37,896

At February 29, 2016, the estimated potential amount of undiscounted future contingent consideration that we expect to pay as a result of all completed acquisitions is approximately $43.0 million. The milestones, including sales projections, associated with the contingent consideration must be reached in future periods ranging from fiscal years 2016 to 2023 in order for the associated consideration to be paid.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

9 Months Ended

Feb. 29, 2016

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

MARKETABLE SECURITIES

Marketable securities, which are principally government agency bonds, auction rate investments and corporate commercial paper, are classified as “available-for-sale securities” and are reported at fair value, with unrealized gains and losses excluded from operations and reported as accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold investments in auction rate securities in order to generate higher than typical money market rate investment returns. Auction rate securities typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate our position in the securities in the near term. As of February 29, 2016 and May 31, 2015, we had $1.7 million and $1.7 million, respectively, in investments in two auction rate securities issued by New York state and local government authorities that failed auctions. The authorities are current in their interest payments on the securities. The auction rate securities mature in 2022 and 2029.

As of February 29, 2016 and May 31, 2015, marketable securities consisted of the following (in thousands of dollars):



As of February 29, 2016	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities
U.S. government agency obligations	$	1,800	$	—	$	(134	)	$	1,666
	$	1,800	$	—	$	(134	)	$	1,666



As of May 31, 2015	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities
U.S. government agency obligations	$	1,825	$	—	$	(136	)	$	1,689
	$	1,825	$	—	$	(136	)	$	1,689

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Feb. 29, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Legal Proceedings The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, regulatory and environmental matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation. AngioDynamics v. biolitec On January 2, 2008, we commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. biolitec, Inc. In this action, we sought judgment against biolitec for defense and indemnification in two lawsuits which we previously settled. Our claims arise out of a Supply and Distribution Agreement (“SDA”) entered into with biolitec on April 1, 2002. On September 27, 2011, the U.S. District Court granted key portions of our motion for summary judgment in our legal case against biolitec. The Court also dismissed biolitec’s counterclaims against us. The court denied one portion of our summary judgment motion, which sought to recover additional costs from biolitec, leaving this for adjudication at trial. On November 8, 2012, the Court granted partial judgment to us in the amount of $23.2 million. Biolitec appealed this judgment. On August 23, 2013, the U.S. Court of Appeals for the Second Circuit dismissed biolitec’s appeal. In October 2009, we commenced an action in the United States District Court for the District of Massachusetts entitled AngioDynamics, Inc. v. biolitec AG and Wolfgang Neuberger. The Complaint in this action was amended in March 2010. This action seeks to recover against biolitec, Inc.’s parent entities and CEO for tortiously interfering with biolitec, Inc.’s contractual obligation to defend and indemnify us, and also seeks to pierce the corporate veil of biolitec, Inc. and to invalidate certain alleged fraudulent transfers in order to hold biolitec, Inc.’s parent entities jointly and severally liable for the alleged breach of the SDA. On September 13, 2012, the Massachusetts Court granted our request for a preliminary injunction prohibiting the downstream merger of biolitec AG with its Austrian subsidiary. On April 1, 2013, the U.S. Court of Appeals for the First Circuit affirmed the preliminary injunction. On January 14, 2014, the District Court entered judgment in our favor as to liability. On March 18, 2014, the District Court entered judgment in our favor against Biolitec AG, Biomed Technology Holdings, Ltd., and Wolfgang Neuberger, jointly and severally, in the amount of $74.9 million. On March 11, 2015, the U.S. Court of Appeals for the First Circuit affirmed the judgment. The defendants petitioned to the U.S. Supreme Court for a writ of certiorari. The Supreme Court denied the petition on November 30, 2015. The defendants have also filed an appeal with the U.S. Court of Appeals for the First Circuit regarding civil contempt sanctions imposed by the Massachusetts District Court as a result of defendants’ completion of the downstream merger in violation of the Court’s injunction. The First Circuit heard oral argument on this latest appeal on January 4, 2016 and has not yet issued an opinion. On February 18, 2016, the Massachusetts District Court issued an order compelling the Massachusetts defendants to provide post-judgment discovery intended to aid us in potentially collecting our judgment. On March 21, 2016, the Massachusetts defendants noticed an appeal from this order. On November 13, 2014, the U.S. District Court for the District of Massachusetts issued summonses to four Biolitec entities - Biolitec U.S., Inc., Biolitec Holding U.S., Inc., Biolitec Medical Devices, Inc., and CeramOptec Industries, Inc. - pursuant to Massachusetts trustee process. We sought to use this process to attach the assets of these entities in order to satisfy our judgment. The trustee process was automatically stayed when the four Biolitec entities filed Chapter 7 petitions in the U.S. Bankruptcy Court for the District of Delaware. However, on November 3, 2015, the Delaware Bankruptcy Court granted our request to modify the automatic stay to allow us to seek a default against the four Biolitec entities pursuant to trustee process. On August 29, 2013, we became co-plaintiffs in an adversary proceeding in the United States Bankruptcy Court for the District of New Jersey entitled Cyganowski, Trustee, et al. v. Biolitec U.S., Inc., et al. In this action, we assert claims of conversion, unjust enrichment, tortious interference, and unfair competition against various biolitec entities for alleged violation of Bankruptcy Court settlement and sale orders under which we acquired certain assets of Biolitec, Inc. On September 3, 2013, we, along with our co-plaintiff, obtained a temporary restraining order against the defendants in this action. On January 22, 2015, the Bankruptcy Court entered a permanent injunction on our behalf for an additional two years. C.R. Bard, Inc. v. AngioDynamics, Inc. On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of our implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard is seeking unspecified damages and other relief. The Court denied Bard’s motion for pre-trial consolidation with separate actions it filed on the same day against Medical Components, Inc. and Smiths Medical ASD, Inc., but had asked for supplemental briefing on the issue of whether to conduct a common Markman hearing. Meanwhile, we filed petitions for reexamination in the US Patent and Trademark Office ("PTO") which seek to invalidate all three patents asserted by Bard in the litigation. Our petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the PTO Board of Appeals and Interferences for all three reexams. The parties completed briefing on the appeals and oral argument was held on June 18, 2015. The Patent Office has issued decisions in the three appeals. In one (issued on March 11, 2016 for US patent no. 7,785,302), the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. In the second (issued on March 24, 2016 for U.S. patent no. 7,959,615), the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third (issued on March 29 for U.S. patent no. 7,947.022) the rejections of all twenty claims under reexamination were affirmed. The Utah Action has been stayed pending final resolution of the PTO process. The Company believes these claims are without merit and intends to defend them vigorously. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. On March 10, 2015, C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. (“Bard”) filed suit in the United States District Court for the District of Delaware claiming certain of the Company’s implantable port products infringe on three U.S. patents held by Bard (the “Delaware Action). Bard is seeking unspecified damages and other relief.The patents asserted in the Delaware Action are different than those asserted in the Utah Action. On June 1, 2015, the Company filed two motions in response to Bard’s Complaint - - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court. On January 12, 2016, the court issued a decision denying both motions. We have since served an Answer and Counterclaim to which Bard has served a Reply. On March 10, 2016, the Court held a case management conference, and, on March 14, 2016, the court entered a Scheduling Order which set, inter alia, a Markman hearing for March 10, 2017, a summary judgment hearing for December 8, 2017 and trial for March 12, 2018. The Company believes these claims are without merit and intends to defend them vigorously. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. Governmental Investigations LC Beads In June 2014 we received a subpoena from the U.S. Department of Justice (the “DOJ”) requesting documents in relation to a criminal and civil investigation the DOJ is conducting regarding BTG International, Inc.’s LC Bead® product beginning in 2003. RITA Medical Systems and AngioDynamics, Inc., after its acquisition of RITA, was the exclusive distributor of LC Beads in the United States from 2006 through December 31, 2011. We are cooperating fully with this investigation and at this time are unable to predict its scope, duration or outcome. EVLT In April 2015 we received a subpoena from the DOJ requesting documents in relation to a criminal and civil investigation the DOJ is conducting regarding purported promotion of certain of AngioDynamics’ VenaCure EVLT products for un-cleared indications. We are cooperating fully with this investigation and at this time are unable to predict its scope, duration or outcome.

Recently Issued Accounting Pronouncements	9 Months Ended
Recently Issued Accounting Pronouncements	Feb. 29, 2016
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09"). ASU 2014-09 provides a single, comprehensive accounting model for revenues arising from contracts with customers that supersedes most of the existing revenue recognition guidance, including industry-specific guidance. Under this model, revenue is recognized at an amount that an entity expects to be entitled to upon transferring control of goods or services to a customer, as opposed to when risks and rewards transfer to a customer under existing revenue recognition guidance. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company is currently in the process of evaluating the impact of ASU 2014-09 on its consolidated financial statements. In June 2014, the FASB issued an ASU that clarified that entities should treat performance targets that can be met after the requisite service period of a share-based payment award as performance conditions that affect vesting. Therefore, an entity would not record compensation expense related to an award for which transfer to the employee is contingent on the entity’s satisfaction of a performance target until it becomes probable that the performance target is met. This ASU is effective for the Company in its first quarter beginning after January 1, 2016 and is not expected to have a material impact on the Company’s consolidated financial statements. In April 2015, the FASB issued ASC Update No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. Update No. 2015-03 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Update No. 2015-03 is effective for annual reporting periods beginning after December 15, 2015 and interim periods within those reporting periods. Early adoption is permitted for financial statements that have not been previously issued. This update is not expected to impact the results of our operations. In July 2015, the FASB issued ASC Update No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. Update No. 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Update No. 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Update No. 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of Update No. 2015-11 is not expected to have a material impact on our financial position or results of operations. In November 2015, the FASB issued ASC Update No. 2015-17, “Balance Sheet Classification of Deferred Taxes” as part of its simplification initiatives. This update requires deferred tax liabilities and assets to be classified as non-current on the consolidated condensed balance sheet for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted. An entity can elect to adopt prospectively or retrospectively to all periods presented. This update was applied retrospectively as of November 30, 2015. The current deferred tax asset balance of $3.5 million and $4.4 million was classified as non-current deferred tax asset for the periods ended November 30, 2015 and May 31, 2015, respectively in the consolidated condensed balance sheet. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10). Update No. 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. Update No. 2016-01 is effective for annual reporting periods beginning after December 15, 2017 and interim periods within those fiscal years and early application is permitted. The adoption of Update No. 2016-01 is not expected to have a material impact on our financial position or results of operations. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term or twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-02 on its consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 01
-Paragraph b
-Subparagraph 6
-Article 10

+ Details

Restructuring	9 Months Ended
Restructuring	Feb. 29, 2016
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING For the three and nine months ended February 28, 2015 we had a restructuring of finance, research and development, and sales and marketing organizations to improve our profitability. As part of the restructuring, we recorded ($0.1) million and $1.1 million of severance and restructuring expense during the three and nine month periods, respectively, which is included in “Acquisition, restructuring and other items, net” in the statements of income. The amount of restructuring expense incurred during the three and nine months ended February 29, 2016 was immaterial.

Subsequent Events	9 Months Ended
Subsequent Events	Feb. 29, 2016
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS On March 1, 2016, AngioDynamics entered into an agreement with Merz North America Inc. to serve as the exclusive distributor of Asclera® (polidocanol) Injection within the vein market in the U.S.. Under the terms of the agreement, the Company paid a total of $4.3 million in fees to Merz which includes exclusive distribution rights and their customer list.

Inventories (Tables)

9 Months Ended

Feb. 29, 2016

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at lower of cost (using the first-in, first-out method) or market. As of February 29, 2016 and May 31, 2015, inventories consisted of the following:



	Feb 29, 2016		May 31, 2015
	(in thousands)
Raw materials	$	28,716	$	28,040
Work in process	11,605		11,910
Finished goods	25,471		27,438
Inventories	$	65,792	$	67,388

Goodwill and Intangible Assets (Tables)

9 Months Ended

Feb. 29, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

As of February 29, 2016 and May 31, 2015, intangible assets consisted of the following:



	February 29, 2016
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
	(in thousands)							(years)
Product technologies	$	148,383	$	(48,815	)	$	99,568	10.2
Customer relationships	86,361		(45,981		)	40,380		12.0
Trademarks	28,470		(5,355		)	23,115		10.7
In process R&D acquired	3,600		—			3,600		Indefinite
Licenses	7,931		(6,514		)	1,417		7.6
Distributor relationships	900		(900		)	—		3.0
	$	275,645	$	(107,565	)	$	168,080



	May 31, 2015
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
	(in thousands)							(years)
Product technologies	$	148,776	$	(41,447	)	$	107,329	10.2
Customer relationships	86,371		(42,813		)	43,558		12.0
Trademarks	28,545		(3,229		)	25,316		10.7
In process R&D acquired	3,600		—			3,600		Indefinite
Licenses	7,913		(5,910		)	2,003		8.3
Distributor relationships	900		(900		)	—		3.0
	$	276,105	$	(94,299	)	$	181,806

Income Taxes (Tables)

9 Months Ended

Feb. 29, 2016

Income Tax Disclosure [Abstract]

Components of Income Tax Expense/(Benefit)

The following table presents the components of income tax expense (benefit) for the three and nine months ended February 29, 2016 and February 28, 2015 (in thousands of dollars):



	Three Months Ended						Nine Months Ended
	Feb 29, 2016			Feb 28, 2015			Feb 29, 2016			Feb 28, 2015
Income (loss) before Income Taxes	$	1,012		$	(11,979	)	$	(390	)	$	(7,732	)
Less discrete book income (expense):
Non-taxable portion of change in fair value of contingent consideration	—			9,229			170			9,229
Taxable portion of revaluation of contingent consideration	480			1,323			480			1,323
Morpheus product recall and discontinuance	—			(6,145		)	—			(6,145		)
Impairment of Automated Power Injector fixed asset	—			(8,200		)	—			(8,200		)
Impairment of indefinite-lived intangible asset	—			(6,400		)	—			(6,400		)
Ordinary income (loss) before income taxes	532			(1,786		)	(1,040		)	2,461

Income tax expense (benefit) based on ordinary income (loss) at estimated tax rates	$	310		$	(461	)	$	(483	)	$	1,276
Discrete tax expense (benefit):
Morpheus product recall and discontinuance	—			(2,243		)	—			(2,243		)
Impairment of Automated Power Injector fixed asset	—			(2,993		)	—			(2,993		)
Taxable gain on revaluation of contingent consideration liability	173			483			173			483
Impairment of indefinite-lived intangible asset	—			(2,336		)	—			(2,336		)
Adjustment for elimination of the ASC 718 APIC pool	115			289			629			974
Retroactive renewal of the Research and Experimentation credit	(302		)	(519		)	(302		)	(519		)
Provision for/resolution of tax audits and contingencies, net	148			—			148			—
Adjustments to prior period tax liabilities	(62		)	63			(66		)	80
Total income tax expense (benefit)	$	382		$	(7,717	)	$	99		$	(5,278	)

Summary of Operating Loss Carryforwards

We have recorded a net deferred tax asset in the US of $19.8 million which includes the benefit of $149.2 million of loss carryforwards, which expire as follows:



Expiration Date	NOL Available (in thousands)
FY 2017	$	802
FY 2019	11,898
FY 2020	8,128
FY 2022	7,526
FY 2023	2,346
FY 2027	20,167
FY 2028	22,527
FY 2029	27,684
FY 2030	28,043
FY 2031	5,647
FY 2032	600
FY 2033	1,345
FY 2034	—
FY 2035	12,513

Earnings Per Share (Tables)

9 Months Ended

Feb. 29, 2016

Earnings Per Share [Abstract]

Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding

The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 29, 2016 and February 28, 2015 (in thousands):



	Three Months Ended		Nine Months Ended
	Feb 29, 2016	Feb 28, 2015	Feb 29, 2016	Feb 28, 2015
Basic	36,146	35,755	36,083	35,568
Effect of dilutive securities	244	—	—	—
Diluted	36,390	35,755	36,083	35,568

Securities excluded as their inclusion would be anti-dilutive	3,394	362	3,038	674

Segment and Geographic Information (Tables)

9 Months Ended

Feb. 29, 2016

Segment Reporting [Abstract]

Summary of Net Sales by Product Category

The table below summarizes net sales by product category (in thousands of dollars):



	Three Months Ended				Nine Months Ended
	Feb 29, 2016		Feb 28, 2015		Feb 29, 2016		Feb 28, 2015
Net sales
Peripheral Vascular	$	49,785	$	46,195	$	147,943	$	142,996
Vascular Access	24,911		26,400		74,576		80,793
Oncology/Surgery	11,998		13,066		35,706		39,062
Supply Agreement	690		936		2,096		3,226
Total	$	87,384	$	86,597	$	260,321	$	266,077

Summary of Net Sales by Geographic Area

The table below presents net sales by geographic area based on external customer location (in thousands of dollars):



	Three Months Ended				Nine Months Ended
	Feb 29, 2016		Feb 28, 2015		Feb 29, 2016		Feb 28, 2015
Net sales
United States	$	69,513	$	68,410	$	208,529	$	208,848
International	17,181		17,251		49,696		54,003
Supply Agreement	690		936		2,096		3,226
Total	$	87,384	$	86,597	$	260,321	$	266,077

Fair Value (Tables)

9 Months Ended

Feb. 29, 2016

Fair Value Disclosures [Abstract]

Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 29, 2016 and May 31, 2015 (in thousands of dollars):



	Fair Value Measurements using inputs considered as:						Fair Value at February 29, 2016
	Level 1		Level 2		Level 3		Fair Value at February 29, 2016
Financial Assets
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,666	$	1,666
Total	—		—		1,666		1,666
Total Financial Assets	$	—	$	—	$	1,666	$	1,666
Financial Liabilities
Interest rate swap agreements	$	—	$	38	$	—	$	38
Contingent liability for acquisition earn out	—		—		37,896		37,896
Total Financial Liabilities	$	—	$	38	$	37,896	$	37,934


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2015
	Level 1		Level 2		Level 3		Fair Value at May 31, 2015
Financial Assets
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,689	$	1,689
Total	—		—		1,689		1,689
Total Financial Assets	$	—	$	—	$	1,689	$	1,689
Financial Liabilities
Interest rate swap agreements	$	—	$	257	$	—	$	257
Contingent liability for acquisition earn out	—		—		47,384		47,384
Total Financial Liabilities	$	—	$	257	$	47,384	$	47,641

Fair Value Measurements Using Significant Unobservable Inputs

The table below presents the changes in fair value components of Level 3 instruments in the nine months ended February 29, 2016 (in thousands of dollars):



	Financial Assets			Financial Liabilities
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)			Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

Balance, May 31, 2015	$	1,689		$	47,384
Total gains or losses (realized/unrealized):
Change in present value of contingent consideration (1)	—			630
Currency (gain) loss from remeasurement	—			(18		)
Included in other comprehensive income (loss)	2			—
Proceeds from sale or maturity of marketable securities	(25		)	—
Contingent consideration payments	—			(10,100		)
Balance, February 29, 2016	$	1,666		$	37,896

Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability

The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 29, 2016 (in thousands of dollars):



	Fair value at		Valuation
	Feb 29, 2016		Technique	Unobservable Input	Range
Revenue based payments	$	35,114	Discounted cash flow	Discount rate	4%
				Probability of achieving sales	75-100%
				Projected fiscal year of payment	2017 - 2023
Milestone based payments	2,782		Discounted cash flow	Discount rate	16%
				Probability of achieving milestone	75-100%
				Projected fiscal year of payment	2017
Total	$	37,896

Marketable Securities (Tables)

9 Months Ended

Feb. 29, 2016

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

As of February 29, 2016 and May 31, 2015, marketable securities consisted of the following (in thousands of dollars):



As of February 29, 2016	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities
U.S. government agency obligations	$	1,800	$	—	$	(134	)	$	1,666
	$	1,800	$	—	$	(134	)	$	1,666



As of May 31, 2015	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities
U.S. government agency obligations	$	1,825	$	—	$	(136	)	$	1,689
	$	1,825	$	—	$	(136	)	$	1,689

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Feb. 29, 2016	May. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 28,716	$ 28,040
Work in process	11,605	11,910
Finished goods	25,471	27,438
Inventories	$ 65,792	$ 67,388

Other Assets (Details) - USD ($) $ in Millions	Dec. 07, 2015	Feb. 29, 2016
Investments in and Advances to Affiliates [Line Items]
Payments to Acquire Equity Method Investments	$ 2.0
Equity Method Investment, Contingent Consideration		$ 4.0
Warrant [Member]
Investments in and Advances to Affiliates [Line Items]
Equity Method Investment, Contingent Consideration		$ 5.0

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Feb. 29, 2016	Feb. 29, 2016	Feb. 28, 2015
Finite-Lived Intangible Assets [Line Items]
Impairment loss on indefinite-lived intangible assets	$ 0	$ 0	$ 6,400
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		18 years
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		2 years

Goodwill and Intangible Assets - Goodwill by Segment (Detail) - USD ($) $ in Thousands	9 Months Ended
	Feb. 29, 2016	Dec. 31, 2015
Goodwill [Line Items]
Goodwill, Beginning Balance	$ 361,252
Goodwill, Ending Balance	$ 361,252
Fair Value Inputs, Discount Rate	12.50%
Percentage of Fair Value Exceeding Its Carrying Value		9.20%
Market Approach Valuation Technique [Member]
Goodwill [Line Items]
Fair Value Assumptions, Calculation Weighted Applied to Various Valuation Method	25.00%
Income Approach Valuation Technique [Member]
Goodwill [Line Items]
Fair Value Assumptions, Calculation Weighted Applied to Various Valuation Method	75.00%

Goodwill and Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Feb. 29, 2016	May. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, excluding goodwill	$ 275,645	$ 276,105
Accumulated amortization	(107,565)	(94,299)
Net carrying value, excluding goodwill	168,080	181,806
Product Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	148,383	148,776
Accumulated amortization	(48,815)	(41,447)
Net carrying value, finite intangible items	$ 99,568	$ 107,329
Weighted avg useful life	10 years 2 months 12 days	10 years 2 months 12 days
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	$ 86,361	$ 86,371
Accumulated amortization	(45,981)	(42,813)
Net carrying value, finite intangible items	$ 40,380	$ 43,558
Weighted avg useful life	12 years	12 years
Trademark NAMIC [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted avg useful life	10 years 8 months 12 days	10 years 8 months 12 days
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	$ 3,600	$ 3,600
Accumulated amortization	0	0
Net carrying value, finite intangible items	3,600	3,600
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	7,931	7,913
Accumulated amortization	(6,514)	(5,910)
Net carrying value, finite intangible items	$ 1,417	$ 2,003
Weighted avg useful life	7 years 7 months 12 days	8 years 3 months 12 days
Distributor Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted avg useful life	3 years	3 years
Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite items	$ 900	$ 900
Accumulated amortization	(900)	(900)
Net carrying value, indefinite items	0	0
Trademark NAMIC [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite items	28,470	28,545
Accumulated amortization	(5,355)	(3,229)
Net carrying value, indefinite items	$ 23,115	$ 25,316

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Feb. 29, 2016	May. 31, 2015
Other Liabilities Disclosure [Abstract]
Payroll and related expenses	$ 9,129	$ 9,911
Royalties	2,211	2,237
Accrued severance	0	175
Other	384	547
Interest rate swap liability	38	257
Accrued Professional Fees	1,420	1,087
Deferred Revenue, Current	794	558
Accrued Rent, Current	29	808
Other	3,974	2,751
Total	$ 17,979	$ 18,331

Long Term Debt - Additional Information (Detail) $ in Thousands	Sep. 19, 2013 USD ($)	Feb. 29, 2016 USD ($)	May. 31, 2015 USD ($)
Debt Instrument [Line Items]
Notional amount of interest rate swap agreement	$ 100,000
Fixed interest rate payments	0.74%
Long-term debt, net of current portion		$ 113,910	$ 128,910
Ratio for debt service coverage	1.35
Ratio of indebtedness to consolidated EBITDA	3.75
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt, net of current portion		41,400
New Credit Agreement [Member]
Debt Instrument [Line Items]
Percentage of increase in interest	2.00%
New Credit Agreement [Member] \| Base Rate [Member] \| JP Morgan Chase [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	0.50%
Percentage of increases leverage ratio base rate, maximum	1.25%
New Credit Agreement [Member] \| Eurodollar [Member] \| JP Morgan Chase [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	1.50%
Percentage of increases leverage ratio base rate, maximum	2.25%
New Credit Agreement [Member] \| Term Loan Facility [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	$ 100,000
Term loan quarterly repayment, year one	5.00%
Term loan quarterly repayment, year two	5.00%
Term loan quarterly repayment, year three	10.00%
Term loan quarterly repayment, year four	15.00%
Term loan quarterly repayment, year five	65.00%
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	$ 100,000
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.20%
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.35%
New Credit Agreement [Member] \| Letters of Credit [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	$ 20,000
New Credit Agreement [Member] \| Swingline Loans [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	5,000
New Credit Agreement [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Initial amount borrowed under revolving facility	$ 41,400
Term Loan [Member]
Debt Instrument [Line Items]
Long-term debt, net of current portion		$ 85,000

Income Taxes - Components of Income Tax Expense/(Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Income Tax Disclosure [Abstract]
Income (loss) before income tax expense (benefit)	$ 1,012	$ (11,979)	$ (390)	$ (7,732)
Non-taxable portion of change in fair value of contingent consideration	0	9,229	170	9,229
Impairment of indefinite-lived intangible asset	0		0	(6,400)
Ordinary income (loss) before income taxes	532	(1,786)	(1,040)	2,461
Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount [Abstract]
Income tax expense / (benefit) based on ordinary income / (loss) at estimated tax rates	310	(461)	(483)	1,276
Discrete tax expense (benefit):
Adjustment for elimination of the ASC 718 APIC pool	115	289	629	974
Adjustments to prior period tax liabilities	(62)	63	(66)	80
Total income tax expense (benefit)	382	(7,717)	99	(5,278)
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	302	519	302	519
Effective Income Tax Reconciliation Fully Reserved Capital Losses	(148)	0	(148)	0
Effective Income Tax Rate Reconciliation, Product Recall	0	(2,243)	0	(2,243)
Effective Income Tax Rate Reconciliation, API Termination	0	(2,993)	0	(2,993)
Effective Income Tax Reconciliation, Gain On Revaluation Of Contingent Consideration Liability	(173)	(483)	(173)	(483)
Effective Income Tax Rate Reconciliation, Impairment Of Intangible Asset	0	$ (2,336)	0	(2,336)
Revaluation Of Taxable Portion Of Contingent Consideration	480		480	1,323
Product Recall And Discontinuance	0		0	6,145
Impairment Of API Fixed Assets	$ 0		$ 0	$ 8,200

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Nov. 30, 2015	May. 31, 2015
Income Tax Examination [Line Items]
Estimated federal statutory income tax rate	46.40%	51.80%
Federal statutory income tax rate			35.00%
Loss carryforwards from acquisitions	$ 149.2		$ 149.2
Domestic Tax Authority [Member]
Income Tax Examination [Line Items]
Net deferred tax asset	19.8		19.8	$ 3.5	$ 4.4
Operating Loss Carryforwards, Valuation Allowance	$ 15.3		$ 15.3

Income Taxes Net Operating Loss Carryforwards (Details) $ in Thousands	Feb. 29, 2016 USD ($)
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	$ 149,200
FY 2017
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	802
FY 2019
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	11,898
FY 2020
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	8,128
FY 2022
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	7,526
FY 2023
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	2,346
FY 2027
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	20,167
FY 2028
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	22,527
FY 2029
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	27,684
FY 2030
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	28,043
FY 2031
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	5,647
FY 2032
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	600
FY 2033
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	1,345
FY 2034
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	0
FY 2035
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	$ 12,513

Share-Based Compensation (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Amount of shares issuable through two stock-based compensation plans	6.8		6.8
Charges against income for share-based payment arrangements	$ 1.6	$ 1.5	$ 4.5	$ 4.4
Unrecognized compensation expenses related to share-based payment arrangements	$ 11.6		$ 11.6

Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Earnings Per Share [Abstract]
Basic	36,146	35,755	36,083	35,568
Effect of dilutive securities	244	0	0	0
Diluted	36,390	35,755	36,083	35,568
Securities excluded as their inclusion would be anti-dilutive	3,394	362	3,038	674

Segment and Geographic Information - Additional Information (Detail)	3 Months Ended
	Aug. 31, 2014 Segment
Segment Reporting [Abstract]
Number of segment	1

Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Segment Reporting Information [Line Items]
Net sales	$ 87,384	$ 86,597	$ 260,321	$ 266,077
Peripheral Vascular [Member]
Segment Reporting Information [Line Items]
Net sales	49,785	46,195	147,943	142,996
Vascular Access [Member]
Segment Reporting Information [Line Items]
Net sales	24,911	26,400	74,576	80,793
Oncology/Surgery [Member]
Segment Reporting Information [Line Items]
Net sales	11,998	13,066	35,706	39,062
Supply Agreement [Member]
Segment Reporting Information [Line Items]
Net sales	$ 690	$ 936	$ 2,096	$ 3,226

Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Net Sales
Net sales	$ 87,384	$ 86,597	$ 260,321	$ 266,077
Supply Agreement [Member]
Net Sales
Net sales	690	936	2,096	3,226
Reportable Geographical Components [Member] \| United States [Member]
Net Sales
Net sales	69,513	68,410	208,529	208,848
Reportable Geographical Components [Member] \| International [Member]
Net Sales
Net sales	17,181	17,251	49,696	54,003
Reportable Geographical Components [Member] \| Supply Agreement [Member]
Net Sales
Net sales	$ 690	$ 936	$ 2,096	$ 3,226

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) - USD ($) $ in Thousands	Feb. 29, 2016	May. 31, 2015
Recurring [Member]
Financial Assets
Marketable securities	$ 1,666	$ 1,689
Total Financial Assets	1,666	1,689
Financial Liabilities
Total Financial Liabilities	37,934	47,641
Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,666	1,689
Interest Rate Swap Agreements [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	38	257
Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	37,896
Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities		47,384
Level 1 [Member] \| Recurring [Member]
Financial Assets
Marketable securities	0	0
Total Financial Assets	0	0
Financial Liabilities
Total Financial Liabilities	0	0
Level 1 [Member] \| Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	0	0
Level 1 [Member] \| Interest Rate Swap Agreements [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0	0
Level 1 [Member] \| Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0
Level 2 [Member] \| Recurring [Member]
Financial Assets
Marketable securities	0	0
Total Financial Assets	0	0
Financial Liabilities
Total Financial Liabilities	38	257
Level 2 [Member] \| Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	0	0
Level 2 [Member] \| Interest Rate Swap Agreements [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	38	257
Level 2 [Member] \| Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0
Level 3 [Member] \| Recurring [Member]
Financial Assets
Marketable securities	1,666	1,689
Total Financial Assets	1,666	1,689
Financial Liabilities
Total Financial Liabilities	37,896	47,384
Level 3 [Member] \| Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,666	1,689
Level 3 [Member] \| Interest Rate Swap Agreements [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0	0
Level 3 [Member] \| Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	$ 37,896	$ 47,384

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) $ in Thousands	9 Months Ended
	Feb. 29, 2016 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in Fair Value of Contingent Consideration	$ 630
Financial assets, begining balance	1,689
Financial liabilities, begining balance	47,384
Currency translation adjustment, assets	0
Currency translation adjustment, liabilities	(18)
Included in other comprehensive income, assets	(2)
Included in other comprehensive income, liabilities	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)	(25)
Contingent consideration - Clinical Devices, assets	0
Financial assets, ending balance	1,666
Financial liabilities, ending balance	37,896
Clinical Devices B.V [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration - Clinical Devices, liabilities	$ (10,100)

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) - USD ($) $ in Thousands	9 Months Ended
	Feb. 29, 2016	May. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
November 30, 2014	$ 37,896	$ 47,384
Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	37,896
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	37,934	47,641
Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities		47,384
Level 3 [Member] \| Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	37,896	47,384
Level 3 [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	37,896	$ 47,384
Level 3 [Member] \| Revenue Based Payments [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
November 30, 2014	$ 35,114
Level 3 [Member] \| Revenue Based Payments [Member] \| Minimum [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	4.00%
Probability of payment	75.00%
Projected fiscal year of payment	2015
Level 3 [Member] \| Revenue Based Payments [Member] \| Maximum [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	10.00%
Probability of payment	100.00%
Projected fiscal year of payment	2022
Level 3 [Member] \| Milestone Based Payments [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
November 30, 2014	$ 2,782
Level 3 [Member] \| Milestone Based Payments [Member] \| Minimum [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	16.00%
Probability of payment	75.00%
Projected fiscal year of payment	2015
Level 3 [Member] \| Milestone Based Payments [Member] \| Maximum [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	20.00%
Probability of payment	100.00%
Projected fiscal year of payment	2017

Fair Value - Summary Showing Reconciliation of the Contingent Payments (Detail) - USD ($) $ in Thousands	9 Months Ended
	Feb. 29, 2016	May. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Translation Adjustment	$ (18)
November 30, 2014	$ 37,896	$ 47,384

Marketable Securities - Additional Information (Detail) $ in Millions	Feb. 29, 2016 USD ($) Investment	May. 31, 2015 USD ($)
Marketable Securities [Abstract]
Investments in auction rate securities that failed auctions \| $	$ 1.7	$ 1.7
Number of investments \| Investment	2

Marketable Securities - Marketable Securities (Detail) - USD ($) $ in Thousands	Feb. 29, 2016	May. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 1,800	$ 1,825
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(134)	(136)
Fair Value	1,666	1,689
U.S. Government Agency Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,800	1,825
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(134)	(136)
Fair Value	$ 1,666	$ 1,689

Commitments and Continfencies - Additional Information (Detail) $ in Millions				9 Months Ended
	Mar. 18, 2014 USD ($)	Nov. 08, 2012 USD ($)	Jan. 02, 2008 Lawsuit	Feb. 29, 2016 patent_claim Petition
Loss Contingencies [Line Items]
Litigation settlement amount \| $	$ 74.9
Biolitec [Member]
Loss Contingencies [Line Items]
Number of lawsuits against biolitec previously settled for which seeking defense and indemnification \| Lawsuit			2
Partial judgment granted \| $		$ 23.2
C.R. Bard, Inc. [Member]
Loss Contingencies [Line Items]
Number of petitions filed for reexamination of patents \| Petition				3
Patent claims \| patent_claim				41,000
Rejected patent claims \| patent_claim				40,000

Recently Issued Accounting Pronouncements (Details) - USD ($) $ in Millions	Feb. 29, 2016	Nov. 30, 2015	May. 31, 2015
Domestic Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Net deferred tax asset	$ 19.8	$ 3.5	$ 4.4

Restructuring - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Feb. 29, 2016	Feb. 29, 2016
Selling and Marketing Expense [Member]
Restructuring Cost and Reserve [Line Items]
Severance expense	$ (0.1)	$ 1.1

Subsequent Events (Details) - USD ($) $ in Millions	Mar. 01, 2016	Dec. 07, 2015
Subsequent Event [Line Items]
Payments to Acquire Equity Method Investments		$ 2.0
Subsequent Event [Member]
Subsequent Event [Line Items]
Payments to Acquire Intangible Assets	$ 4.3

Fair Value - Additional Information (Detail) $ in Millions	Feb. 29, 2016 USD ($)
Fair Value Disclosures [Abstract]
Potential amount of undiscounted future contingent consideration	$ 43.0